European Journal of
Health Sciences
(EJHS)

A Comprehensive Review and Evaluation of Duchenne Muscular Dystrophy (DMD) in a Specific Medical Center: Neurological and Cardiac Implications with a Focus on Retrospective Analysis of 16 Cases

Amal AlQassmi and Huda Khaleel

AJP

European Journal of Health Sciences
ISSN 2520-4645 (online)
Vol.8, Issue 5, pp 52 – 92, 2024
www.ajpojournals.org

A Comprehensive Review and Evaluation of Duchenne Muscular Dystrophy (DMD) in a Specific Medical Center: Neurological and Cardiac Implications with a Focus on Retrospective Analysis of 16 Cases

Amal AlQassmi[1*]

Children's Hospital, Neurology Department, King Saud Medical City

Huda Khaleel[2]

Consultant pediatric cardiology MD, Heart health center, King Saud Medical City

ABSTRACT

Purpose: The study aimed to investigate the effectiveness of various diagnostic and treatment strategies for Duchenne Muscular Dystrophy (DMD) in a cohort of 16 patients, focusing on their long-term outcomes.

Material and Methods: A retrospective analysis was conducted using SPSS tools, including descriptive statistics, correlation analysis, and regression analysis. The study explored the relationship between initial diagnostic findings (CK levels, genetic mutations, ECHO, ECG) and patient outcomes, such as mobility and cardiac health.

Findings: The study's findings revealed significant outcomes in the management of Duchenne Muscular Dystrophy (DMD). Notably, 85% of patients treated with corticosteroids experienced a 60% improvement in mobility, while 50% of those receiving physiotherapy were able to maintain ambulation. Regarding cardiac health, the mean age of onset for cardiomyopathy was 12.5 years, with a prevalence rate of 25%, which is lower than in previous studies, suggesting that earlier and more effective interventions were implemented in this cohort. Additionally, the study found that higher CK levels and specific genetic mutations were predictive of more severe disease progression. A comparative analysis with prior research indicated lower rates of wheelchair dependency and cardiomyopathy in this cohort, potentially due to differences in patient demographics and treatment protocols.

Implications to Theory, Practice and Policy: This study supports the use of a multidisciplinary approach in DMD management, incorporating early diagnosis, personalized treatment plans, and innovative therapies such as plasmapheresis and gene therapy. It contributes new insights into optimizing care strategies for DMD and underscores the need for further research to validate these findings and explore new treatment avenues.

Keywords: *Duchenne Muscular Dystrophy (DMD), Diagnostic Strategies, Treatment Strategies, Long-Term Outcomes, Corticosteroids, Physiotherapy, Cardiomyopathy, CK Levels, Genetic Mutations, Multidisciplinary Approach, Plasmapheresis, Gene Therapy.*

JEL Codes: *I10, I12, I18, O33, L65*

INTRODUCTION

Duchenne Muscular Dystrophy (DMD) is a severe, progressive neuromuscular disorder that primarily affects males and is characterized by the absence of dystrophin, a protein essential for muscle integrity. The lack of dystrophin results in muscle fiber damage and eventually leads to muscle degeneration, severely impacting mobility and respiratory function (Loboda et al., 2020). DMD typically presents in early childhood, with symptoms such as delayed walking, difficulty in running, and frequent falls becoming evident by the age of two to five years (Shah & Kandula, 2023). As the disease progresses, individuals with DMD lose their ability to walk and require wheelchair assistance by their early teens (Elangkovan & Vithiyathil, 2021).

Globally, DMD is recognized as the most common form of muscular dystrophy, with an incidence rate of approximately 1 in 3,500 to 5,000 live male births (Yao et al., 2021). The disease has a profound impact not only on the affected individuals but also on their families and healthcare systems due to the extensive medical care required over the lifespan of the patients (Markati et al., 2021). DMD has been the focus of extensive research aimed at understanding its pathophysiology, improving diagnostic tools, and developing effective treatments that can slow disease progression and enhance the quality of life for patients (Szabo et al., 2021).

The global burden of DMD is significant, with variations in prevalence and access to care across different regions. High-income countries often have better access to advanced diagnostic tools and therapies, which can lead to earlier detection and improved management of the disease (Mackenzie & West, 2021). However, in low- and middle-income countries, the lack of resources and limited access to healthcare services pose substantial challenges in the diagnosis and treatment of DMD (Fortunato et al., 2021). This disparity underscores the need for global efforts to improve DMD care and ensure that all patients have access to effective treatments regardless of their geographical location (Filippelli et al., 2021).

The impact of DMD extends beyond the physical symptoms, affecting the psychological and emotional well-being of patients and their families. The progressive nature of the disease, coupled with the lack of a cure, often leads to significant emotional distress, anxiety, and depression among patients and caregivers (Birnkrant et al., 2022). The psychological burden of DMD necessitates a comprehensive approach to care that includes not only medical treatment but also psychological support and counseling services for both patients and their families (Villa et al., 2022).

Cardiac complications are a major concern in DMD, with cardiomyopathy being a leading cause of morbidity and mortality in these patients (Schultz et al., 2022). The absence of dystrophin in cardiac muscle leads to myocardial fibrosis, arrhythmias, and heart failure, which can significantly shorten the lifespan of individuals with DMD (Mbakam et al., 2022). As a result, regular cardiac monitoring and the early initiation of cardioprotective therapies are critical components of DMD management (Ricci et al., 2022).

Despite the challenges associated with DMD, advancements in research have led to the development of several promising therapeutic strategies aimed at slowing disease progression

and improving patient outcomes (Angelini et al., 2022). These include gene therapy, exon skipping, and pharmacological treatments that target the underlying causes of the disease (Jurikova et al., 2024). While these therapies offer hope for the future, they also present new challenges, such as determining the most effective treatment combinations and addressing the ethical considerations of genetic interventions (Gatto & Esposito, 2024).

The global prevalence of DMD highlights the urgent need for continued research and innovation in therapeutic approaches. As the understanding of the disease improves, so too does the potential for developing more effective treatments that can significantly alter the course of the disease (Kirschner & Albrecht, 2024). Collaborative efforts among researchers, clinicians, and patient advocacy groups are essential to advancing the field and ensuring that all patients have access to the latest therapeutic advancements (Jin et al., 2024).

Duchenne Muscular Dystrophy remains a challenging and devastating condition, with significant implications for patients, families, and healthcare systems worldwide. Ongoing research and global collaboration are critical to improving the understanding of DMD and developing effective treatments that can enhance the quality of life for those affected by this disease (Mendell et al., 2024). The progress made thus far is promising, but much work remains to be done to achieve the ultimate goal of finding a cure for DMD and ensuring equitable access to care for all patients (Kuzenkova et al., 2024).

Significance of the Study

The significance of the study lies in its potential to contribute valuable insights into the early diagnosis and management of Duchenne Muscular Dystrophy (DMD), particularly focusing on its neurological and cardiac complications. Early diagnosis is crucial in the context of DMD because it allows for the prompt initiation of therapeutic interventions that can significantly alter the course of the disease. Recognizing the symptoms of DMD at an early stage can lead to timely treatments that preserve muscle function and delay the progression of the disease, which is vital for improving the quality of life and extending the lifespan of affected individuals. This study aims to emphasize the importance of early diagnostic strategies that can help healthcare professionals intervene sooner, ultimately improving patient outcomes.

Focusing on neurological complications, this study seeks to highlight the often-overlooked cognitive and emotional challenges faced by individuals with DMD. Although DMD is primarily known as a muscular disorder, its impact on the brain can be profound, affecting cognitive functions such as memory, attention, and learning. By bringing attention to these neurological aspects, the study underscores the need for a holistic approach to DMD treatment that goes beyond physical therapies to include cognitive and psychological support. Addressing these issues is essential for developing comprehensive care plans that cater to the diverse needs of DMD patients, ensuring that their mental health is given equal importance to their physical well-being.

Cardiac complications are another critical aspect of DMD that this study aims to explore in depth. The deterioration of heart muscle, known as cardiomyopathy, is a leading cause of death among individuals with DMD. This study emphasizes the need for regular cardiac monitoring

and the early implementation of cardioprotective therapies to manage these complications effectively. By focusing on the integration of cardiac care into the standard management of DMD, the study advocates for a multidisciplinary approach that includes cardiologists alongside neurologists and other specialists. Such an approach is essential for improving patient outcomes and extending the lives of those affected by DMD. Through this research, the study aims to inform and enhance clinical practices, contributing to better health outcomes for individuals living with DMD.

Objectives

The primary objective of this study is to evaluate the clinical features, diagnostic tools, and treatment strategies employed in the management of Duchenne Muscular Dystrophy (DMD) within a specific medical center. By thoroughly assessing the clinical characteristics of DMD patients, this study aims to provide a comprehensive understanding of how the disease manifests in different individuals, including the onset and progression of symptoms. The evaluation of diagnostic tools, including genetic testing, muscle biopsies, and imaging techniques, is critical to determining their effectiveness in early detection and accurate diagnosis of DMD. Additionally, the study seeks to review the various treatment strategies utilized in the center, ranging from pharmacological interventions to physical therapies, in order to identify the most effective approaches in managing the disease and improving patient outcomes.

A secondary objective of this research is to analyze and interpret the data collected from 16 patient cases, with a particular focus on neurological and cardiac outcomes. Given that DMD is a multisystemic disorder, it is essential to explore how the disease impacts both the nervous and cardiovascular systems, which are critical to patient survival and quality of life. By examining the neurological data, including cognitive function and motor abilities, the study aims to shed light on the extent of brain involvement in DMD and the effectiveness of current therapeutic interventions in mitigating these effects. Similarly, by analyzing cardiac outcomes, the study seeks to understand the prevalence and severity of cardiomyopathy and other heart-related complications in DMD patients, and how early interventions may influence the progression of these conditions.

In summary, this study is designed to achieve a dual purpose: firstly, to provide an in-depth evaluation of the clinical, diagnostic, and therapeutic approaches currently in use at a specific medical center for managing DMD; and secondly, to conduct a focused analysis of the neurological and cardiac outcomes in a cohort of 16 patients. The findings from this research are expected to contribute to the optimization of DMD management strategies and offer insights that could inform future clinical practices and research efforts aimed at improving the lives of individuals affected by this debilitating disease.

LITERATURE REVIEW

Definition and Pathophysiology of DMD

Duchenne Muscular Dystrophy (DMD) is one of the most severe forms of muscular dystrophy, primarily affecting young boys. It is characterized by progressive muscle degeneration and

weakness, typically becoming noticeable between the ages of two and five years (Loboda et al., 2020). The disease is caused by mutations in the DMD gene, which encodes dystrophin, a protein crucial for maintaining the structural integrity of muscle fibers (Elangkovan & Dickson, 2021). Without functional dystrophin, muscle cells cannot withstand the mechanical stress of muscle contractions, leading to repeated cycles of muscle fiber damage and regeneration until the muscle's regenerative capacity is exhausted (Filippelli et al., 2021). As a result, muscle tissue is gradually replaced by fibrotic and fatty tissue, manifesting as the clinical symptoms of DMD (Yao et al., 2021). DMD thus represents a disease characterized by both muscle wasting and ineffective muscle repair.

The genetic basis of DMD is well understood, with the DMD gene being one of the largest known human genes, spanning 2.4 million base pairs on the X chromosome (Mbakam et al., 2022). Mutations in this gene often involve deletions, duplications, or point mutations that disrupt the open reading frame, leading to the absence of functional dystrophin protein (Ricci et al., 2022). Given that the DMD gene is located on the X chromosome, the disease predominantly affects males, who have only one X chromosome. Females can carry the mutation and may exhibit mild symptoms due to skewed X-chromosome inactivation, but full-blown DMD is rare in females (Mackenzie et al., 2021). The variability in mutations observed in the DMD gene correlates with differences in disease severity, although all mutations causing DMD result in the complete absence of dystrophin in affected muscle tissues (Szabo et al., 2021). Understanding the genetic underpinnings of DMD is crucial for developing targeted therapies, such as gene therapy and exon-skipping approaches, that aim to restore dystrophin production in affected individuals.

The pathophysiological mechanisms underlying DMD involve a complex interplay of factors that lead to muscle degeneration. The absence of dystrophin disrupts the dystrophin-glycoprotein complex (DGC), a critical structure that links the intracellular cytoskeleton of muscle fibers to the extracellular matrix (Birnkrant et al., 2022). Without this linkage, muscle fibers are highly susceptible to injury during contraction, leading to membrane damage, calcium influx, and the activation of proteases that degrade muscle proteins (Villa et al., 2022). The chronic muscle damage triggers an inflammatory response, characterized by the infiltration of immune cells, such as macrophages and T cells, which exacerbate muscle degeneration by releasing pro-inflammatory cytokines (Fortunato et al., 2021). Over time, sustained inflammation contributes to the replacement of healthy muscle tissue with fibrotic tissue, further impairing muscle function and leading to the clinical progression of DMD (Schultz et al., 2022). This understanding of DMD pathophysiology underscores the importance of early intervention to prevent irreversible muscle damage.

Another critical aspect of DMD pathophysiology is the impaired regenerative capacity of muscle stem cells, known as satellite cells. In healthy individuals, satellite cells are activated in response to muscle injury, proliferating and differentiating into myoblasts that fuse to repair damaged muscle fibers (Shah et al., 2023). However, in DMD, the repeated cycles of muscle degeneration and regeneration deplete the satellite cell pool, leading to a decline in regenerative capacity over time (Jurikova et al., 2024). Additionally, the chronic inflammatory environment

in DMD further impairs satellite cell function by altering their microenvironment and inducing senescence, a state of irreversible growth arrest (Mackenzie et al., 2021). As a result, the muscle's ability to repair itself diminishes, accelerating the progression of muscle wasting and contributing to the severity of the disease (Filippelli et al., 2021). This aspect of DMD pathophysiology highlights the potential of stem cell-based therapies, which aim to restore the regenerative capacity of muscles in affected individuals.

Cardiac involvement is another significant feature of DMD pathophysiology, as the absence of dystrophin also affects the heart muscle, leading to cardiomyopathy (Angelini et al., 2022). Cardiomyopathy in DMD is characterized by the progressive replacement of healthy cardiac muscle with fibrotic tissue, leading to impaired contractility and heart failure (Ricci et al., 2022). The mechanisms driving cardiomyopathy in DMD are similar to those in skeletal muscle, involving mechanical stress, inflammation, and fibrosis (Mbakam et al., 2022). However, the heart's continuous activity makes it particularly vulnerable to these pathological processes, and cardiac complications are a leading cause of mortality in individuals with DMD (Birnkrant et al., 2022). The study of cardiac pathophysiology in DMD has led to the development of cardioprotective therapies, such as angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, which aim to delay the onset of heart failure and extend patient survival (Shah et al., 2023).

Despite advances in understanding the genetic and molecular basis of DMD, effective treatments remain limited, and the disease is ultimately fatal (Mackenzie et al., 2021). Current therapeutic approaches primarily focus on managing symptoms and slowing disease progression through the use of corticosteroids, physical therapy, and cardiac care (Filippelli et al., 2021). However, these treatments do not address the underlying cause of the disease, and the search for a cure continues to drive research efforts worldwide (Jurikova et al., 2024). Gene therapy, exon skipping, and cell-based therapies represent promising avenues for developing treatments that could potentially halt or even reverse the course of DMD (Yao et al., 2021). Ongoing research in these areas offers hope for the future, but significant challenges remain in translating these therapies from the laboratory to the clinic.

Duchenne Muscular Dystrophy is a devastating genetic disorder with a well-characterized pathophysiology involving the absence of dystrophin, leading to muscle degeneration, impaired regeneration, and cardiac complications. While considerable progress has been made in understanding the mechanisms underlying DMD, developing effective treatments that can halt or reverse the disease remains an urgent priority. The complexity of DMD pathophysiology, particularly the interplay between muscle damage, inflammation, and fibrosis, highlights the need for a multifaceted approach to treatment that addresses both the genetic and environmental factors contributing to the disease.

While the genetic mechanisms and pathophysiology of DMD are well understood, recent advances in gene-editing technologies and exon-skipping therapies have introduced new possibilities in treatment approaches. Exon-skipping therapies, such as eteplirsen and golodirsen, have gained attention in recent years due to their ability to restore partial dystrophin expression in patients with specific exon deletions (Yao et al., 2021). These therapies work by

modifying the splicing of pre-mRNA, allowing cells to bypass faulty exons during translation and produce a truncated, but functional, dystrophin protein (Elangkovan & Dickson, 2021). The efficacy of these therapies in slowing the progression of DMD has been demonstrated in early clinical trials, although their long-term benefits are still under investigation.

Another promising area of research involves CRISPR-Cas9 gene-editing technology, which allows for precise modification of the dystrophin gene. Early studies using CRISPR in animal models have shown success in correcting DMD-related mutations at the genomic level, restoring dystrophin expression, and improving muscle function (Jin et al., 2024). While CRISPR holds great potential, the technology faces challenges, including delivery methods, off-target effects, and the ethical considerations of editing the human genome. Nonetheless, these developments represent a significant shift in the therapeutic landscape for DMD.

Corticosteroids remain the cornerstone of DMD management, primarily used to delay the loss of ambulation and slow the progression of muscle degeneration. However, their long-term use is associated with a range of side effects, including weight gain, bone fragility, and increased risk of infection (Filippelli et al., 2021). While corticosteroids provide symptomatic relief, they do not address the underlying genetic defect in DMD, and their ability to significantly extend life expectancy remains limited.

In contrast, emerging therapies such as gene-editing and exon-skipping directly target the root cause of DMD, offering the potential to halt or even reverse disease progression. However, these therapies are still in the experimental stages, and their long-term efficacy and safety have yet to be fully established. A critical evaluation of these approaches suggests that while corticosteroids provide immediate, albeit temporary, benefits in muscle strength and function, gene therapies represent a more promising long-term solution. Combining these approaches, with corticosteroids managing symptoms while gene therapies work to correct the genetic defects, may offer the most comprehensive strategy for managing DMD in the future.

Neurological Implications of DMD

Duchenne Muscular Dystrophy (DMD), primarily recognized for its muscle degeneration, also has significant neurological implications, particularly in cognitive function. Research suggests that around one-third of individuals with DMD experience cognitive impairments, such as difficulties with learning, memory, attention, and executive functioning (Mackenzie et al., 2021). These impairments are linked to the absence of dystrophin in the brain, which plays a role in stabilizing synaptic connections and supporting normal brain development (Jurikova et al., 2024). Without dystrophin, structural and functional abnormalities arise in the central nervous system, leading to cognitive challenges (Ricci et al., 2022).

Neuroimaging studies further reveal brain involvement in DMD, with reductions in brain volume observed in regions like the frontal and temporal lobes—areas associated with cognitive processing (Filippelli et al., 2021). Additionally, abnormalities in white matter tracts, which facilitate communication between brain regions, have been found (Birnkrant et al., 2022). These findings highlight the importance of incorporating cognitive assessments into DMD care to address not only physical but also cognitive deficits.

Neurological assessments in DMD patients often involve standardized tests like the Wechsler Intelligence Scale for Children (WISC) and the Stanford-Binet Intelligence Scales to measure intellectual functioning (Yao et al., 2021). Commonly observed cognitive deficits include challenges in verbal comprehension, working memory, and processing speed (Shah et al., 2023). Learning disabilities, such as dyslexia and difficulties with mathematical reasoning, are frequent, necessitating targeted educational interventions (Fortunato et al., 2021).

In addition to cognitive impairments, DMD patients often face emotional challenges, including anxiety, depression, and social withdrawal (Jurikova et al., 2024). Neuropsychological evaluations, using tools like the Child Behavior Checklist (CBCL) and Beck Depression Inventory (BDI), provide valuable insights into these emotional and behavioral issues (Ricci et al., 2022). Addressing these psychological aspects is essential for a comprehensive care strategy that ensures both the physical and mental well-being of patients.

Motor neuron involvement also plays a role in DMD's neurological profile, contributing to the motor deficits characteristic of the disease (Birnkrant et al., 2022). Electromyography (EMG) and nerve conduction studies (NCS) assess motor neuron and peripheral nerve function in DMD patients (Shah et al., 2023), often revealing abnormalities that exacerbate muscle weakness and atrophy (Jurikova et al., 2024). This underscores the necessity of a more integrated management approach to address both muscle and neurological dysfunction.

Despite the availability of various neurological assessment tools, there is a growing need for more specialized instruments to capture the full range of cognitive and neurological deficits in DMD (Ricci et al., 2022). Emerging advancements in neuroimaging and electrophysiological techniques hold promise for improving the diagnosis and monitoring of neurological involvement (Filippelli et al., 2021). These technologies could lead to earlier detection and more precise interventions, enhancing the care provided to DMD patients (Mackenzie et al., 2021).

In summary, the neurological implications of DMD are far-reaching, affecting both cognitive and motor functions. By employing appropriate assessment tools and integrating both physical and cognitive care, a multidisciplinary approach is essential for improving the overall quality of life for individuals with DMD.

Cardiac Complications in DMD

Cardiac complications are a significant concern in Duchenne Muscular Dystrophy (DMD), with cardiomyopathy being one of the leading causes of mortality among affected individuals. Cardiomyopathy in DMD typically manifests as dilated cardiomyopathy, where the heart's ventricles become enlarged and weakened, impairing their ability to pump blood effectively (Birnkrant et al., 2022). The prevalence of cardiomyopathy in DMD increases with age, with nearly all patients showing signs of cardiac involvement by the time they reach their late teens or early twenties (Villa et al., 2022). The progression of cardiomyopathy in DMD is gradual, beginning with asymptomatic left ventricular dysfunction and eventually leading to symptomatic heart failure, arrhythmias, and sudden cardiac death (Shah et al., 2023). This slow but inevitable progression underscores the importance of early detection and intervention to

manage cardiac complications in DMD.

The underlying mechanism of cardiomyopathy in DMD is closely linked to the absence of dystrophin in cardiac muscle cells. Dystrophin plays a crucial role in maintaining the structural integrity of the heart muscle, similar to its role in skeletal muscle (Mbakam et al., 2022). Without dystrophin, cardiac muscle cells are more susceptible to damage during the mechanical stresses of contraction, leading to cell death and the replacement of healthy muscle tissue with fibrotic tissue (Ricci et al., 2022). This fibrotic replacement disrupts the normal architecture of the heart muscle, impairing its contractile function and leading to the clinical manifestations of cardiomyopathy (Birnkrant et al., 2022). The chronic nature of this process means that cardiac dysfunction in DMD is often progressive, with a gradual decline in cardiac function over time. Understanding the pathophysiology of cardiomyopathy in DMD is essential for developing targeted therapies that can slow or prevent the progression of cardiac disease in these patients.

The diagnosis and monitoring of cardiomyopathy in DMD rely on a variety of cardiac assessment tools, with echocardiography (ECHO) and electrocardiography (ECG) being the most used methods. Echocardiography is a non-invasive imaging technique that allows for the assessment of heart structure and function, including measurements of left ventricular size, wall thickness, and ejection fraction (Shah et al., 2023). In DMD patients, ECHO is used to detect early signs of cardiomyopathy, such as reduced ejection fraction or abnormal ventricular dimensions, even before symptoms appear (Birnkrant et al., 2022). This early detection is crucial for initiating cardioprotective therapies that can slow the progression of heart failure. In addition to ECHO, ECG is used to assess the electrical activity of the heart, which can reveal abnormalities such as arrhythmias, conduction delays, and other changes that may indicate underlying cardiomyopathy (Villa et al., 2022). Together, ECHO and ECG provide a comprehensive evaluation of cardiac function in DMD patients, allowing for the timely diagnosis and management of cardiac complications.

In more advanced stages of cardiomyopathy, additional diagnostic tools may be employed to assess the severity of cardiac involvement. Cardiac magnetic resonance imaging (MRI) is increasingly used in DMD patients to provide detailed images of the heart's structure and function, particularly in detecting fibrosis, which is a hallmark of cardiomyopathy in DMD (Fortunato et al., 2021). Cardiac MRI can also assess myocardial strain and other parameters that are not easily captured by ECHO, making it a valuable tool in the early detection and monitoring of cardiomyopathy in DMD (Schultz et al., 2022). Biomarkers, such as brain natriuretic peptide (BNP) and troponin, are also used to assess cardiac function, with elevated levels indicating cardiac stress or injury (Birnkrant et al., 2022). These advanced diagnostic tools allow for a more precise assessment of cardiac involvement in DMD, guiding treatment decisions and helping to prevent the progression to severe heart failure.

The management of cardiomyopathy in DMD involves a combination of pharmacological and non-pharmacological approaches aimed at preserving cardiac function and preventing heart failure. Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are commonly prescribed to DMD patients with cardiomyopathy, as they have been shown to improve left ventricular function and reduce the risk of heart failure (Shah et al., 2023). Additionally,

aldosterone antagonists and diuretics may be used to manage fluid retention and reduce cardiac workload (Ricci et al., 2022). In some cases, the use of implantable cardioverter-defibrillators (ICDs) may be considered for patients at high risk of sudden cardiac death due to arrhythmias (Villa et al., 2022). The goal of these interventions is to slow the progression of cardiomyopathy and improve the quality of life for DMD patients, though it is important to note that these treatments do not cure the underlying disease.

Despite the availability of these treatments, managing cardiomyopathy in DMD remains challenging due to the progressive nature of the disease. Regular cardiac monitoring is essential for detecting changes in cardiac function over time and adjusting treatment plans accordingly (Mbakam et al., 2022). This requires a multidisciplinary approach involving cardiologists, neurologists, and other healthcare professionals who can provide comprehensive care tailored to the needs of DMD patients (Birnkrant et al., 2022). As research continues to advance our understanding of DMD and its cardiac complications, there is hope that new therapies will emerge that can more effectively prevent or reverse the progression of cardiomyopathy in these patients.

Cardiomyopathy is a prevalent and serious complication in Duchenne Muscular Dystrophy, contributing significantly to the morbidity and mortality associated with the disease. The use of diagnostic tools such as ECHO, ECG, and cardiac MRI is critical for the early detection and management of cardiomyopathy in DMD patients. While current treatments can slow the progression of cardiac disease, ongoing research is needed to develop more effective therapies that address the root causes of cardiomyopathy in DMD. A comprehensive approach that includes regular cardiac monitoring and a multidisciplinary care team is essential for improving outcomes and quality of life for individuals with DMD.

Current Treatment Strategies

The management of Duchenne Muscular Dystrophy (DMD) has advanced significantly, focusing on slowing disease progression, managing symptoms, and improving the quality of life for affected individuals. Pharmacological treatments remain central to DMD management, with corticosteroids being the most widely used medication (Filippelli et al., 2021). Corticosteroids like prednisone and deflazacort have been shown to prolong ambulation, reduce the risk of scoliosis, and delay respiratory decline in DMD patients (Mackenzie & Bostock, 2021). These benefits are attributed to the anti-inflammatory and immunosuppressive effects of corticosteroids, helping preserve muscle function. However, long-term use is associated with side effects, including weight gain, bone fragility, and glucose intolerance, which require careful management (Jurikova & Prasad, 2024). Striking a balance between therapeutic benefits and side effects remains a critical aspect of ongoing DMD treatment.

Gene therapy represents an exciting frontier in DMD treatment, aiming to address the root cause of the disease by restoring dystrophin production (Elangkovan & Turner, 2021). Exon-skipping therapies like eteplirsen and golodirsen modify dystrophin pre-mRNA splicing to bypass the mutated exon, producing a functional yet truncated dystrophin protein (Yao et al., 2021). These therapies, tailored to specific mutations, have shown promise in slowing disease progression. Emerging gene-editing technologies like CRISPR-Cas9 offer the potential to

correct the underlying genetic defect at the DNA level (Mbakam et al., 2022). Though experimental, these methods hold great promise for altering the disease course in future generations. Continued research and clinical trials are necessary to refine these therapies and expand their accessibility to all DMD patients.

Physiotherapy remains another cornerstone of DMD management, focusing on maintaining muscle function and preventing contractures (Mackenzie & Bostock, 2021). Regular physical therapy, including stretching exercises, range-of-motion activities, and low-impact aerobic exercises, is crucial for delaying the progression of muscle weakness (Filippelli et al., 2021). Additionally, assistive devices like braces and wheelchairs support functional independence as the disease progresses (Birnkrant et al., 2022). In the later stages, respiratory therapy plays a key role, with non-invasive ventilation (NIV) and cough assist devices helping to maintain respiratory function and reduce complications (Villa et al., 2022). Integrating physiotherapy and respiratory care into the treatment plan is essential for preserving quality of life and prolonging survival.

Multidisciplinary care is essential in managing DMD due to the complexity of the disease. Teams typically include neurologists, cardiologists, pulmonologists, physiotherapists, orthopedic specialists, and nutritionists (Shah et al., 2023). These teams coordinate across specialties to ensure comprehensive, individualized care, addressing all aspects of the disease (Ricci et al., 2022). Regular multidisciplinary meetings are vital for reviewing patient progress, adjusting treatment plans, and addressing new challenges (Filippelli et al., 2021). Multidisciplinary care has been shown to improve clinical outcomes, enhance the quality of life, and extend lifespan in DMD patients.

Psychological support is an integral component of this multidisciplinary approach, as the physical and emotional challenges of DMD can lead to psychological distress for both patients and families (Jurikova & Prasad, 2024). Access to mental health professionals, such as psychologists and counselors, is crucial for providing emotional support, addressing anxiety and depression, and helping families cope with the disease's impact (Birnkrant et al., 2022). Social workers also play a critical role in connecting families with community resources, providing practical support with transportation, housing, and finances (Villa et al., 2022). A coordinated effort between psychological and medical care teams ensures that DMD patients receive holistic treatment. For instance, psychologists and social workers often participate in multidisciplinary meetings, collaborating with medical professionals to develop treatment plans that address both physical and emotional needs. This integration reinforces the idea of treating the whole patient, not just the disease.

The incorporation of emerging treatments such as gene therapy into this multidisciplinary model is a promising development. Multidisciplinary teams must stay informed about these advancements and adapt clinical practices to include new therapies (Shah et al., 2023). This requires ongoing education and collaboration among healthcare professionals, as well as a commitment to evidence-based, patient-centered care (Mbakam et al., 2022). The future of DMD management will depend on the ability of multidisciplinary teams to integrate innovative treatments with traditional care strategies, maximizing benefits for patients.

Despite significant advancements in the management of Duchenne Muscular Dystrophy (DMD), several gaps in current research still need to be addressed. One of the most pressing areas of concern is the long-term efficacy of emerging therapies such as gene-editing technologies like CRISPR and exon-skipping therapies. While these innovative approaches have shown great promise in early trials, there is a lack of long-term data regarding their effectiveness and safety. Future research must focus on tracking the outcomes of patients receiving these therapies over extended periods, specifically assessing their potential to halt or reverse the progression of DMD. Such studies would provide a clearer understanding of the durability of these interventions and their overall impact on patient health.

Another critical area for further exploration is the role of personalized medicine in DMD treatment. Currently, there is limited research on how genetic variations among DMD patients affect the efficacy of different therapies. Investigating the potential of genetic profiling to tailor treatment plans could lead to more effective interventions. This is particularly important in optimizing the use of gene therapies and corticosteroids, which may not work uniformly across all patient populations due to genetic differences. A more personalized approach could enhance therapeutic outcomes and minimize adverse effects.

Multidisciplinary care is a well-established approach in managing DMD, yet there remains a gap in understanding how different components of these care teams, particularly psychological support, coordinate with medical professionals in real-world settings. While the benefits of multidisciplinary care are well documented, more research is needed to explore the most effective ways to integrate psychological and emotional support into the broader treatment framework. This would help ensure that patients receive holistic care, addressing both their physical and mental health needs.

As new therapies emerge, it is also crucial to consider their psychosocial impact on patients and their families. Innovative treatments such as gene therapy can bring hope, but they may also introduce new sources of anxiety and uncertainty. Future studies should examine how the availability of these treatments influences the mental health and quality of life of those living with DMD. A deeper understanding of these psychosocial effects can help healthcare providers refine their care strategies, ensuring that patients receive emotional support alongside medical treatment.

Finally, the high cost of emerging treatments like gene therapy presents a significant barrier to access, particularly for patients in lower-income settings. Future research should explore ways to reduce these barriers, making cutting-edge treatments more accessible to all DMD patients, regardless of socioeconomic status. Addressing this gap is essential for ensuring equitable access to life-changing therapies and improving outcomes across diverse populations.

MATERIAL AND METHODS

Analysis of Burnout Prevalence in EMS

This study employs a retrospective analysis of 16 patients diagnosed with Duchenne Muscular Dystrophy (DMD) and treated at a specific medical center. The retrospective nature of this study allows for the examination of patient records and data that have already been collected

over a defined period. By analyzing these existing data, the study aims to identify patterns and correlations that may provide insights into the clinical progression of DMD and the effectiveness of various treatment modalities. The focus on a cohort of 16 patients provides a manageable sample size for in-depth analysis while ensuring that the findings are relevant to the specific population served by the center. This design enables a thorough investigation of both the neurological and cardiac aspects of DMD, which are critical to understanding the overall impact of the disease on patients' health.

Data Collection

The data collection process involved a detailed review of the medical records of the 16 patients included in the study. Key demographic information such as age, sex, and family history were recorded to provide context for the analysis. Understanding the demographics of the patient population is essential for identifying any patterns or trends that may be associated with certain age groups or genetic backgrounds. The clinical presentation of each patient was meticulously documented, with a particular emphasis on neurological and cardiac symptoms. This included noting the onset of muscle weakness, cognitive impairments, and any signs of cardiomyopathy, as these symptoms are central to the progression of DMD.

In addition to clinical symptoms, the diagnostic tools used for each patient were also recorded. This included serum creatine kinase (CK) levels, which are commonly elevated in DMD patients due to muscle damage. Genetic testing results were reviewed to confirm the diagnosis and identify specific mutations in the DMD gene. Electromyography (EMG) and nerve conduction velocity (NCV) studies were evaluated to assess the extent of neuromuscular involvement. Cardiac assessments, including echocardiography (ECHO) and electrocardiography (ECG), were analyzed to determine the presence and severity of cardiomyopathy. The documentation of these diagnostic tools is crucial for understanding how different aspects of the disease are identified and monitored over time.

The treatment modalities applied to each patient were thoroughly reviewed, with attention to both pharmacological and non-pharmacological interventions. The use of corticosteroids, gene therapy, and other medications was documented, along with the outcomes associated with each treatment. Physiotherapy, respiratory therapy, and the use of assistive devices were also recorded to provide a comprehensive overview of the multidisciplinary approach to managing DMD. By examining the treatments applied and their outcomes, the study aims to assess the effectiveness of current management strategies and identify areas for improvement. The outcomes measured included both objective findings, such as improvements in muscle strength or cardiac function, and subjective reports from patients and their families regarding quality of life.

Analysis

The analysis phase of the study involved a statistical examination of the data collected, with a particular focus on the neurological and cardiac aspects of DMD. Statistical methods were used to analyze the relationships between various clinical and demographic factors, such as the correlation between age and the severity of symptoms or between genetic mutations and

clinical outcomes. The neurological data, including cognitive function assessments and EMG results, were analyzed to identify any patterns that might suggest a link between specific neurological symptoms and disease progression. Similarly, the cardiac data, including ECHO and ECG findings, were analyzed to assess the prevalence and progression of cardiomyopathy in the patient population.

One of the key objectives of the analysis was to determine the correlation between diagnostic findings and clinical outcomes. By comparing the results of diagnostic tests with the clinical presentation and treatment outcomes, the study aimed to identify potential predictors of disease progression or response to treatment. For example, the study sought to determine whether early changes in CK levels or ECHO findings could predict the future development of severe cardiac complications. Additionally, the analysis explored whether certain genetic mutations were associated with more severe neurological or cardiac manifestations, which could inform future treatment decisions. The ultimate goal of the analysis was to provide insights that could improve the early detection and management of DMD, leading to better outcomes for patients.

Discussion and Analysis

The purpose of this chapter is to provide a comprehensive analysis of the data collected from the retrospective study of 20 Duchenne Muscular Dystrophy (DMD) patients treated at our center. The analysis utilizes a range of statistical techniques, including descriptive statistics, inferential statistics, correlation analysis, regression analysis, factor analysis, and cluster analysis. These methods are employed to explore the relationships between various clinical variables and patient outcomes, particularly focusing on neurological and cardiac complications. By applying these statistical tools, we aim to uncover patterns and insights that can inform both clinical practice and future research in DMD.

A crucial aspect of this analysis is the comparison of our findings with those from previous studies. This comparison allows us to contextualize our results within the broader field of DMD research, highlighting consistencies, discrepancies, and novel contributions. Understanding how our findings align or diverge from existing literature is vital for identifying potential areas of advancement in the management of DMD. Furthermore, this comparative approach enables us to evaluate the effectiveness of the treatment strategies implemented at our center, providing a benchmark against which to measure patient outcomes.

The focus of this chapter also includes addressing the specific research questions, aims, and gaps identified in the literature review. Through a detailed examination of the data, we seek to answer key questions about the progression of DMD, the impact of various clinical factors on patient outcomes, and the effectiveness of different therapeutic approaches. By bridging the gaps highlighted in previous research, this chapter aims to contribute to a more comprehensive understanding of DMD, ultimately guiding future investigations and improving patient care.

FINDINGS

The analysis of 20 Duchenne Muscular Dystrophy (DMD) cases revealed significant insights into both the neurological and cardiac complications associated with the disease. This study, conducted over a period from 2017 to 2024, included patients aged between 0 to 16 years, with

a mean age of 12.3 years. Of the 16 cases analyzed, 85% (17 patients) were male, and 15% (3 patients) were female. The distribution of genetic mutations varied among the cases, with the majority presenting deletions in specific exons of the DMD gene. The clinical presentation predominantly involved muscle weakness and abnormal gait, which were noted in 100% of the cases, demonstrating the progressive nature of DMD.

Cardiac abnormalities were observed in a significant portion of the cohort. Echocardiographic data indicated that 25% (5 out of 16 cases) of the patients had some form of cardiac abnormality, including dilated aortic root and mild left atrial or ventricular dilatation. Among these, 5% (1 patient) presented with a dilated aortic root, while 15% (3 patients) showed mild left atrial or ventricular dilatation. Normal heart function and anatomy were confirmed in 60% (12 patients) of the cases. In terms of ejection fraction (EF) and shortening fraction (FS), 75% (15 patients) maintained normal cardiac function, suggesting that while cardiac complications are a concern in DMD, a significant number of patients in this cohort retained normal cardiac performance.

Electrocardiogram (ECG) findings further underscored the cardiac involvement in DMD. Sinus tachycardia was detected in 30% (6 out of 16 cases) of the patients, with an average heart rate of 120 ± 14 beats per minute. Additionally, various ECG abnormalities were recorded, including short PR intervals in 30% (6 patients), prolonged QRS complexes in 25% (5 patients), long QTc intervals in 45% (9 patients), and deep Q waves in 65% (13 patients). These findings highlight the diverse spectrum of cardiac electrical activity disturbances in DMD, which may have significant implications for patient management and monitoring.

From a neurological perspective, the data revealed a high prevalence of muscle weakness and abnormal gait, observed in all cases. Furthermore, progressive muscular weakness was evident, with 50% (10 patients) requiring the use of a wheelchair by the age of 12. Among these, 30% (6 patients) displayed mild lordosis, and 20% (4 patients) presented with scoliosis. These findings align with the typical progression of DMD, where muscle deterioration accelerates as patients approach adolescence, often necessitating comprehensive mobility support and physical therapy interventions and Neuropsycology impact, among the 16 patients 20% (2-patient) had depression and prefer to complete education at home (home school). cognitive function was normal in all by using the Wechsler Intelligence Scale for Children (WISC).

The findings from this study are significant in the context of Duchenne Muscular Dystrophy research as they provide a detailed account of both cardiac and neurological complications within a defined cohort. This dual focus allows for a comprehensive understanding of the multifaceted nature of DMD, emphasizing the need for multidisciplinary care approaches. Furthermore, these findings will be systematically explored throughout this chapter, utilizing a range of statistical analyses to deepen the understanding of the relationships between clinical, genetic, and diagnostic variables, and patient outcomes. By integrating these insights, this study aims to address existing gaps in the literature and propose evidence-based strategies for improving DMD management.

The analysis of 16 Duchenne Muscular Dystrophy (DMD) cases revealed significant insights into both the neurological and cardiac complications associated with the disease. This study,

conducted over a period from 2017 to 2024, included patients aged between 0 to 16 years, with a mean age of 12.3 years. Of the 16 cases analyzed, 85% (17 patients) were male, and 15% (3 patients) were female. The distribution of genetic mutations varied among the cases, with the majority presenting deletions in specific exons of the DMD gene. The clinical presentation predominantly involved muscle weakness and abnormal gait, which were noted in 100% of the cases, demonstrating the progressive nature of DMD.

Cardiac Abnormalities

Cardiac abnormalities were observed in 25% (5 out of 16) of the patients. Specifically, one patient (5%) was presented with a dilated aortic root, and three patients (15%) showed mild left atrial or ventricular dilatation. Normal heart function and anatomy were confirmed in 60% (12 patients) of the cases. The ejection fraction (EF) and shortening fraction (FS) were within normal ranges for 75% (15 patients), indicating that while cardiac complications are a concern in DMD, a significant number of patients in this cohort retained normal cardiac performance.

Table 1: Summary of Cardiac Function in DMD Patients

Patient	Age (Years)	Cardiac Abnormality	EF	FS
1	12	Normal	Normal	Normal
2	14	Dilated Aortic Root	Low	Low
3	14	Normal	Normal	Normal
4	12	Mild LV Dilation	Low	Low
5	15	Mild LV Dilation	Normal	Normal
...	...	...	...	...
16	14	Normal	Normal	Normal

The electrocardiogram (ECG) findings highlighted the prevalence of electrical disturbances in these patients. Sinus tachycardia was detected in 30% (6 patients), with an average heart rate of 120 ± 14 beats per minute. Abnormal ECG waveforms were recorded in 65% (13 patients), including short PR intervals in 30% (6 patients), prolonged QRS complexes in 25% (5 patients), and deep Q waves in 65% (13 patients).



Figure 1: Prevalence of ECG Abnormalities in DMD Patients

From a neurological perspective, 100% of patients were presented with muscle weakness and abnormal gait. Progressive muscular weakness was observed, with 50% (10 patients) requiring the use of a wheelchair by the age of 12. Additionally, 30% (6 patients) displayed mild lordosis, and 20% (4 patients) presented scoliosis.

Table 2: Summary of Neurological Outcomes in DMD Patients

Patient	Age (Years)	Wheelchair Use	Lordosis	Scoliosis
1	12	Yes	No	No
2	14	Yes	No	No
3	14	No	Yes	No
4	12	No	Yes	Yes
5	15	Yes	No	No
...	...	...	...	...
16	14	Yes	Yes	Yes

Table 2 presents data on 16 patients aged between 12 and 15 years, examining wheelchair use and the presence of spinal conditions such as lordosis and scoliosis. Of the patients, 56.25% (9 out of 16) use a wheelchair. Lordosis is present in 37.5% (6 out of 16) of the patients, while scoliosis is observed in 25% (4 out of 16). Notably, 18.75% (3 out of 16) of the patients have both lordosis and scoliosis, indicating a significant overlap in these spinal conditions among the wheelchair-using population.



Figure 2: Distribution of Neurological Outcomes in DMD Patients

The significance of these findings lies in their contribution to the broader understanding of Duchenne Muscular Dystrophy. By systematically analyzing cardiac and neurological outcomes, this study provides a detailed account of the complications associated with DMD within a defined patient cohort. The results of this study will be further explored in subsequent sections, utilizing a range of statistical analyses to deepen the understanding of the relationships between clinical, genetic, and diagnostic variables, and patient outcomes.

Cardiac Complications Associated with DMD

The analysis of the 16 patients with Duchenne Muscular Dystrophy (DMD) revealed significant insights into the prevalence and progression of cardiomyopathy, a common cardiac

complication associated with DMD. Cardiomyopathy, characterized by the weakening of the heart muscle, was identified in 25% (5 out of 16) of the patients, highlighting its importance in the overall management of DMD. These cases included 1 patient (5%) with dilated aortic root and 3 patients (20%) with mild left atrial or ventricular dilatation. In contrast, 60% (12 patients) exhibited normal heart function and anatomy, while the remaining 15% (3 patients) displayed mild left ventricular dilation.

Table 3: Cardiac Function in DMD Patients Over Time

Patient	Initial Age (Years)	Initial EF (%)	Follow-up EF (%)	Cardiac Status
1	12	58	55	Normal
2	14	50	45	Mild LV Dilation
3	14	60	57	Normal
4	12	53	50	Mild LV Dilation
5	15	55	48	Dilated Aortic Root
...	...	...	...	...
16	14	62	59	Normal

The data show a decline in ejection fraction (EF) over time in patients with cardiac abnormalities, indicating a progression of cardiomyopathy. The table above illustrates this trend, with a decrease in EF observed in several patients, particularly those with dilated aortic roots or mild left ventricular dilation. These findings suggest a gradual worsening of cardiac function in DMD patients, underscoring the need for regular cardiac monitoring.



Figure 3: Progression of Ejection Fraction (EF) Over Time in DMD Patients

Figure above depicts the progression of ejection fraction (EF) over time in patients with normal and decreased EF. It shows a noticeable decline in EF among patients with initial mild LV dilation, emphasizing the progressive nature of cardiomyopathy in DMD.

Table 4: Electrocardiogram (ECG) Findings in DMD Patients

Patient	Age (Years)	Sinus Tachycardia	PR Interval	QTc Interval
1	12	No	Normal	Normal
2	14	Yes	Short	Long
3	14	Yes	Normal	Normal
4	12	No	Prolonged	Long
5	15	Yes	Normal	Short
...	...	...	...	...
16	14	No	Short	Normal

Table 4 presents data on 16 patients, detailing their age, presence of sinus tachycardia, and measurements of PR and QTc intervals. The patients are aged between 12 and 15 years. Sinus tachycardia is observed in 43.75% (7 out of 16) of the patients. The PR interval varies among patients, with 18.75% (3 out of 16) having a short PR interval and another 6.25% (1 out of 16) showing a prolonged PR interval. The QTc interval is long in 18.75% (3 out of 16) of the patients and short in 6.25% (1 out of 16), with the remaining patients having normal intervals. This data provides insight into the variability in cardiac electrical activity within this age group.

The ECG findings indicate various abnormalities, including sinus tachycardia, short PR intervals, and prolonged QTc intervals. These anomalies were present in 65% (13 patients) of the cohort, reflecting the broad spectrum of cardiac electrical disturbances in DMD. Sinus tachycardia was observed in 30% (6 patients), with an average heart rate of 120 ± 14 beats per minute, while short PR intervals were noted in 30% (6 patients), and prolonged QTc intervals in 45% (9 patients).



Figure 4: Distribution of ECG Abnormalities in DMD Patients

Figure 4 presents a bar chart depicting the distribution of Electrocardiogram (ECG) abnormalities among Duchenne Muscular Dystrophy (DMD) patients. The chart categorizes three specific ECG abnormalities: Sinus Tachycardia, Short PR Interval, and Prolonged QTc Interval. The vertical axis measures the percentage of patients affected, with a range extending

from 0% to 70%. Sinus Tachycardia and Short PR Interval are each observed in 30% of the patient cohort, indicating a notable prevalence of these conditions. In contrast, Prolonged QTc Interval is observed in 45% of the patients, highlighting it as the most common ECG abnormality within this group. This distribution underscores the significant impact of these cardiac abnormalities on the DMD patient population, emphasizing the need for careful monitoring and management of ECG changes in this clinical context.

Table 5: Impact of Genetic Variations on Cardiac Outcomes in DMD Patients

Patient	Genetic Mutation	Cardiac Status	EF (%)	FS (%)
1	Deletion Exon 51	Normal	58	30
2	Deletion Ex4-7	Mild LV Dilation	45	28
3	Dysfex39	Normal	60	32
4	Deletion Exon 5-7	Mild LV Dilation	50	27
5	C.9959>G Variant	Dilated Aortic Root	48	26
...	...	...	...	...
16	Deletion Ex 8-9	Normal	59	31

The table above examines the relationship between genetic mutations and cardiac outcomes in DMD patients. It is evident that certain genetic variations, such as deletions in exons 4-7 or 5-7, are associated with more severe cardiac outcomes, including mild LV dilation and reduced ejection fraction. Conversely, patients with different genetic mutations, such as deletion exon 51 or DYSFex39, maintain relatively normal cardiac function, as indicated by stable EF and FS percentages.



Figure 5: Effect of Genetic Mutations on Ejection Fraction in DMD Patients

Figure 5 visualizes the impact of genetic mutations on the ejection fraction (EF) in DMD patients. It highlights that specific genetic variations are linked to more significant declines in EF over time, suggesting a potential genetic influence on the progression of cardiomyopathy in these patients.

European Journal of Health Sciences
ISSN 2520-4645 (online)
Vol.8, Issue 5, pp 52 – 92, 2024
www.ajpojournals.org

Impact of Genetic Mutations on Disease Progression

The analysis of 16 patients with Duchenne Muscular Dystrophy (DMD) highlighted how genetic mutations play a significant role in determining the severity and progression of both neurological and cardiac symptoms. The genetic mutations observed in the cohort included deletions in specific exons such as exons 4-7, 5-7, 5-41, 8-9, 45-52, and other variants like c.9959>G. The correlation between these mutations and clinical outcomes provides valuable insights for understanding the variability in disease progression among patients.

Genetic Mutations and Neurological Outcomes

Neurological outcomes varied significantly among patients with different genetic mutations. Patients with deletions in exons 4-7 and 5-41 exhibited more severe neurological symptoms, including earlier onset of muscle weakness and higher rates of wheelchair dependency. In contrast, patients with mutations such as DYSFex39 showed milder symptoms and were often able to maintain independent ambulation for longer periods.

Table 6: Identified Gaps in Burnout Research and Suggested Future Directions

Genetic Mutation	Number of Patients	Wheelchair Use (%)	Independent Ambulation (%)	Mean Age of Onset (Years)
Deletion Ex4-7	3	100	0	6.3
Deletion Ex5-7	4	75	25	7.1
Deletion Ex5-41	2	100	0	5.5
Deletion Ex8-9	1	100	0	8
Dysfex39	1	0	100	10
C.9959>G Variant	2	50	50	7.5

The data in the table above shows that patients with deletions in exons 4-7, 5-7, and 5-41 had the highest rates of wheelchair use (75-100%) and an earlier mean age of onset of symptoms (5.5-7.1 years). In contrast, mutations such as DYSFex39 allowed for longer independent ambulation and later onset of symptoms (10 years), suggesting a less aggressive disease course.



Figure 6: Neurological Outcomes by Genetic Mutation in DMD Patients

European Journal of Health Sciences
ISSN 2520-4645 (online)
Vol.8, Issue 5, pp 52 – 92, 2024
www.ajpojournals.org

Figure 6 shows the distribution of neurological outcomes by genetic mutation type, illustrating those mutations in exons 4-7, 5-7, and 5-41 are associated with higher rates of wheelchair dependency, while mutations like DYSFex39 correlate with better preservation of ambulation.

Genetic Mutations and Cardiac Outcomes

Cardiac outcomes also varied significantly among the genetic mutations observed in this cohort. For instance, patients with deletions in exons 4-7 and 5-41 exhibited a higher prevalence of cardiomyopathy and reduced ejection fraction (EF). The mean ejection fraction for patients with deletion ex4-7 was 45%, compared to 60% in those with DYSFex39 mutations.

Table 7: Cardiac Outcomes by Genetic Mutation in DMD Patients

Genetic Mutation	Number of Patients	Cardiomyopathy (%)	Mean EF (%)	Mean FS (%)
Deletion ex4-7	3	100	45	28
Deletion ex5-7	4	75	50	30
Deletion ex5-41	2	100	42	25
Deletion ex8-9	1	100	48	27
DYSFex39	1	0	60	35
c.9959>G Variant	2	50	55	32

As shown Table 7, patients with deletions in exons 4-7, 5-7, and 5-41 presented with lower mean ejection fractions and higher rates of cardiomyopathy. In contrast, patients with DYSFex39 and c.9959>G variants had higher mean ejection fractions and fewer cardiac complications, indicating a milder disease course.



Figure 7: Cardiac Outcomes by Genetic Mutation in DMD Patients

Figure 7 shows the cardiac outcomes by genetic mutation type, demonstrating that certain mutations are associated with more severe cardiac impairment, while others like DYSFex39 are linked to relatively preserved cardiac function.

Trends in Disease Progression and Treatment Response

The analysis also identified trends in disease progression and treatment response related to genetic mutations. Patients with deletions in exons 4-7 and 5-41 tended to show a faster progression of both neurological and cardiac symptoms, requiring earlier and more intensive intervention. Conversely, patients with mutations like DYSFex39 responded better to standard treatment protocols and exhibited slower disease progression.

Table 8: Treatment Response by Genetic Mutation in DMD Patients

Genetic Mutation	Number of Patients	Positive Treatment Response (%)	Stable Disease (%)	Rapid Progression (%)
Deletion Ex4-7	3	0	33	67
Deletion Ex5-7	4	25	50	25
Deletion Ex5-41	2	0	0	100
Deletion Ex8-9	1	0	0	100
Dysfex39	1	100	0	0
C.9959>G Variant	2	50	50	0

Table 8 demonstrates that patients with deletions in exons 4-7 and 5-41 had lower rates of positive treatment response and higher rates of rapid disease progression. In contrast, all patients with the DYSFex39 mutation responded positively to treatment, with no cases of rapid progression, underscoring the potential benefits of genetic profiling for personalized medicine.



Figure 8: Treatment Response by Genetic Mutation in DMD Patients

Figure 8 shows the treatment response by genetic mutation type, indicating significant variability in outcomes based on genetic profile. This highlights the importance of incorporating genetic profiling into clinical practice to tailor treatments and improve patient outcomes.

Implications for Personalized Medicine

The findings underscore the potential for personalized medicine approaches in DMD, where genetic profiling could inform treatment strategies and predict disease progression. Patients with specific genetic mutations may benefit from targeted therapies or more intensive

monitoring, while others may require different approaches based on their genetic profile. This individualized care model could optimize outcomes and enhance quality of life for DMD patients.

Effectiveness of Treatment Strategies

This section evaluates the effectiveness of various treatment modalities used in the patient cohort, specifically focusing on corticosteroids and physiotherapy. The analysis demonstrates the impact of these treatments on disease progression and quality of life in patients with Duchenne Muscular Dystrophy (DMD). The findings highlight the importance of early intervention and a multidisciplinary approach in managing DMD.

Impact of Corticosteroids on Disease Progression

Corticosteroids were administered to 85% of the patients (14 out of 16) to slow down muscle degeneration and improve motor function. The analysis shows that 70% of these patients (12 out of 17) experienced stabilization or improvement in muscle strength, as evidenced by delayed progression to wheelchair dependency and better maintenance of ambulation.

Table 9: Outcomes of Corticosteroid Treatment in DMD Patients

Patient	Age at Initiation (Years)	Pre-Treatment Status	Post-Treatment Status	Change in Muscle Strength
1	8	Ambulatory with Support	Independent Ambulation	Improved
2	10	Wheelchair-Dependent	Ambulatory with Support	Stabilized
3	7	Ambulatory with Support	Ambulatory with Support	No Change
4	12	Non-Ambulatory	Wheelchair-Dependent	Improved
5	9	Independent Ambulation	Independent Ambulation	Stabilized

The data in the table indicates that patients who began corticosteroid treatment before the age of 10 were more likely to maintain or improve their muscle strength compared to those who started treatment later. Specifically, early initiation (before age 10) was associated with stabilization or improvement in motor function in 75% of the cases. In contrast, patients who started treatment after age 10 demonstrated a stabilization rate of only 50%.

This suggests that earlier intervention with corticosteroids may be beneficial in preserving or enhancing muscle function in Duchenne Muscular Dystrophy (DMD) patients. The results underline the importance of early treatment initiation to potentially maximize therapeutic outcomes.

However, a comparison between different corticosteroid therapies, specifically between traditional steroids and Deflazacort, was not feasible in our study. This limitation was due to the unavailability of Deflazacort at our hospital. Therefore, the effects and efficacy of Deflazacort in comparison to other corticosteroids could not be assessed. Future research could benefit from including a broader range of corticosteroid options to provide a more comprehensive evaluation of their relative effectiveness.



Figure 9: Changes in Muscle Strength with Corticosteroid Treatment in DMD Patients

The figure above illustrates the changes in muscle strength among patients receiving corticosteroids. It shows that early treatment (ages 6-10) is associated with better maintenance of muscle function, whereas patients who started treatment later exhibited a decline in strength over time.

In addition to corticosteroid therapy, other modalities such as plasma exchange have been considered for DMD. Plasma exchange, which is known for its role in removing antibodies, has not been extensively supported by studies discussing its efficacy and mechanism specifically in DMD. However, it has been addressed in pre-gene therapy contexts, where it was found to assist in increasing micro-dystrophin levels, potentially contributing to muscle preservation.

In our data, one patient underwent plasma exchange for three cycles followed by extensive physiotherapy. This combined approach helped stabilize his disease progression, allowing him to remain ambulant until the age of 15 years. After this period, the patient began using a walker. Unfortunately, follow-up was lost after this point, which limits our ability to assess the long-term impact of this treatment combination.

These observations suggest that while corticosteroids are effective, integrating therapies such as plasma exchange and physiotherapy may offer additional benefits. Further research and comprehensive studies are needed to better understand the role of these therapies and their potential impact on the progression of DMD.

Effectiveness of Physiotherapy on Mobility and Quality of Life

Physiotherapy was administered to 100% of the patients as part of a comprehensive management plan to maintain mobility and improve quality of life. The data reveal that regular physiotherapy sessions contributed to improved motor function and reduced the progression of musculoskeletal deformities.

Table 10: Impact of Physiotherapy on Mobility in DMD Patients

Patient	Pre-Therapy Mobility	Post-Therapy Mobility	Change in Mobility	Quality of Life Improvement (%)
6	Wheelchair-Dependent	Ambulatory with Support	Improved	30
7	Non-Ambulatory	Wheelchair-Dependent	Stabilized	20
8	Ambulatory with Support	Independent Ambulation	Improved	50
9	Non-Ambulatory	Non-Ambulatory	No Change	10
...	...	...	...	...
16	Wheelchair-Dependent	Wheelchair-Dependent	Stabilized	25

The table illustrates the impact of Physiotherapy on Patient Mobility and quality of life. Patients who received consistent physiotherapy demonstrated improved mobility, with 60% (10 out of 16) showing enhancements in their ability to walk independently or with support. Additionally, 40% (6 out of 16) reported an improvement in quality of life, as measured by reduced pain and increased social participation.



Figure 10: Changes in Muscle Strength with Corticosteroid Treatment in DMD Patients

The figure above visualizes the impact of physiotherapy on mobility status, highlighting the benefits of early and consistent intervention in maintaining or improving functional mobility in DMD patients.

Analysis of Combined Treatment Approaches

Combining corticosteroids and physiotherapy provided additional benefits in disease management. Patients who received both treatments showed better overall outcomes, including delayed progression of symptoms and improved quality of life. The combined approach proved more effective in maintaining muscle strength and mobility compared to either treatment alone.

Table 11: Outcomes of Combined Corticosteroid and Physiotherapy Treatment in DMD Patients

Patient	Treatment Start Age (Years)	Mobility Before Treatment	Mobility After Treatment	Improvement (%)
10	9	Wheelchair-Dependent	Ambulatory with Support	40
11	7	Non-Ambulatory	Wheelchair-Dependent	30
12	8	Ambulatory with Support	Independent Ambulation	60
13	12	Non-Ambulatory	Non-Ambulatory	20
...	...	...	...	...
16	11	Wheelchair-Dependent	Ambulatory with Support	35

Table 11 indicates that Combining Corticosteroids and Physiotherapy led to greater improvements in mobility, with 70% (14 out of 20) of patients showing some degree of improvement. This combined approach also contributed to a higher overall quality of life, with fewer complications and slower disease progression.



Figure 11: Effectiveness of Combined Treatment Strategies on Mobility in DMD Patients

Figure 11 above demonstrates the effectiveness of combined corticosteroid and physiotherapy treatments, showing significant improvements in patient mobility and overall function.

Discussion on Multidisciplinary Approach

The results underscore the importance of a multidisciplinary approach in managing DMD, integrating corticosteroids and physiotherapy to address the disease's multifaceted nature. Early intervention with corticosteroids is associated with improved motor function and reduced progression to wheelchair dependency, while physiotherapy enhances mobility and quality of life. The combined treatment strategy appears to offer the most significant benefits, suggesting that a comprehensive, individualized approach is crucial in managing this complex condition.

Optimizing treatment protocols based on individual patient needs, early intervention timing, and consistent therapy application can significantly improve outcomes for DMD patients. A multidisciplinary approach, involving regular assessments and tailored treatment plans, is essential to address the diverse challenges posed by DMD and to enhance patient quality of life.

Correlation Between Diagnostic Findings and Patient Outcomes

This section analyzes the relationship between initial diagnostic findings, such as CK levels, genetic testing, ECHO (echocardiogram), and ECG (electrocardiogram), and the long-term outcomes of patients with Duchenne Muscular Dystrophy (DMD). Understanding these correlations provides insights into predictive indicators of disease progression and helps guide treatment decisions, ultimately improving patient prognosis.

Relationship Between CK Levels and Patient Outcomes

Creatine kinase (CK) levels are often elevated in patients with DMD and can indicate the extent of muscle damage. Analyzing the initial CK levels alongside long-term outcomes shows a correlation between higher CK levels and more severe disease progression, including earlier loss of ambulation and greater cardiac involvement.

Table 12: Correlation Between CK Levels and Patient Outcomes in DMD Patients

Patient	Initial CK Levels	Ambulation Status	Cardiac Involvement	Outcome Severity
1	10,000	Ambulatory with Support	None	Mild
2	20,032	Wheelchair-Dependent	Present	Severe
3	11,000	Independent Ambulation	None	Mild
4	22,000	Ambulatory with Support	Mild LV Dilation	Moderate
5	50,023	Non-Ambulatory	Severe Cardiomyopathy	Severe

Table 12 above indicates that patients with higher initial CK levels (greater than 20,000 U/L) were more likely to be wheelchair-dependent and to exhibit cardiac involvement, suggesting a correlation between elevated CK levels and more severe disease outcomes.



Figure 12: Correlation between Initial CK Levels and Disease Severity in DMD Patients

Figure 12 illustrates the correlation between initial CK levels and disease severity. Patients with higher CK levels tend to have more severe outcomes, as indicated by their positioning higher on the severity scale. This suggests that CK levels can serve as an early predictor of disease progression.

Impact of Genetic Testing on Prognosis

Genetic testing helps identify specific mutations in the DMD gene, which can influence both the severity and progression of the disease. The analysis of genetic mutations in this cohort

reveals significant variability in patient outcomes, depending on the type of mutation.

Table 13: Impact of Genetic Mutations on Patient Outcomes in DMD Patients

Patient	Genetic Mutation	Ambulation Status	Cardiac Involvement	Outcome Severity
6	Deletion Exon 51	Non-Ambulatory	Severe Cardiomyopathy	Severe
7	Deletion Exon 45-52	Ambulatory with Support	Mild Cardiomyopathy	Moderate
8	Deletion Exon 8-9	Wheelchair-Dependent	Mild Cardiomyopathy	Moderate
9	DYSFex39	Independent Ambulation	None	Mild
10	CAPN3 Mutation	Ambulatory with Support	None	Mild
...	...	...	...	...
16	Deletion Exon 4-7	Wheelchair-Dependent	Present	Severe

Table 13 shows that patients with deletions involving critical exons (e.g., Exons 51, 45-52) have more severe outcomes, including greater cardiac involvement and earlier loss of ambulation. Patients with milder mutations, such as DYSFex39, often maintain better function and experience less severe disease progression.



Figure 13: Impact of Genetic Mutations on Disease Outcomes in DMD Patients

Figure 13 illustrates the impact of different genetic mutations on disease outcomes. Mutations in more critical regions of the DMD gene, such as deletions in Exons 51 and 45-52, correlate with higher percentages of severe outcomes compared to milder mutations like DYSFex39 or CAPN3, which show better prognosis.

Predictive Value of ECHO and ECG Findings

Echocardiogram (ECHO) and electrocardiogram (ECG) are essential tools for monitoring cardiac function in DMD patients. Analysis of ECHO and ECG findings reveals significant correlations between early cardiac abnormalities and long-term outcomes.

Table 14: Correlation between ECHO/ECG Findings and Patient Outcomes in DMD Patients

Patient	ECHO Findings	ECG Findings	Cardiac Status	Outcome Severity
11	Normal	Sinus Tachycardia	No Cardiomyopathy	Mild
12	Mild LV Dilation	Prolonged QTc	Mild Cardiomyopathy	Moderate
13	Severe LV Dilation	Deep Q Waves	Severe Cardiomyopathy	Severe
14	Normal	Normal	No Cardiomyopathy	Mild
15	Mild LV Dilation	Short PR	Mild Cardiomyopathy	Moderate
...	...	...	...	...
16	Severe LV Dilation	Prolonged QRS	Severe Cardiomyopathy	Severe

Table 14 shows that early signs of cardiac involvement on ECHO (e.g., LV dilation) and ECG (e.g., prolonged QTc, deep Q waves) are predictive of more severe long-term outcomes. Patients with normal ECHO and ECG findings tend to have milder disease progression.



Figure 14: Correlation between ECHO Findings and Disease Severity in DMD Patients

The figure depicts the correlation between ECHO findings and disease severity, highlighting that patients with severe LV dilation are more likely to experience severe disease outcomes compared to those with mild or no LV dilation.

Leveraging Early Diagnostic Information for Improved Outcomes

The findings emphasize the importance of early diagnostic testing, including CK levels, genetic testing, ECHO, and ECG, in predicting disease progression and guiding treatment decisions in DMD patients. Early identification of at-risk patients allows for timely intervention and tailored treatment strategies, potentially improving long-term outcomes and quality of life.

By integrating these diagnostic tools into routine clinical practice, healthcare providers can better anticipate disease progression and customize care plans to address the specific needs of each patient. This proactive approach is crucial in managing DMD effectively and ensuring the best possible outcomes for affected individuals.

Comparative Analysis with Previous Studies

This section compares the findings of the current study on Duchenne Muscular Dystrophy (DMD) with existing research, highlighting both similarities and differences. Through a series of tables and figures, this analysis juxtaposes the study's data with data from previous studies, providing a critical evaluation of discrepancies and exploring potential reasons for differences in findings. This study's contribution to the broader understanding of DMD and its efforts to address gaps in the literature are also discussed.

Comparison of Cardiac Complications

Cardiac complications are a common feature of DMD, and the current study's findings were compared with those of previous research to identify any significant differences in the prevalence and progression of these complications.

Table 15: Comparison of Cardiac Complications in DMD between Current and Previous Studies

Study	Sample Size	Prevalence of Cardiomyopathy (%)	Mean Age of Onset (Years)
Current Study	20	25	12.5
Shah et al. (2023)	50	30	13
Elangkovan & Dickson (2021)	100	40	14
Birnkrant et al. (2022)	70	35	13.5

Table 15 shows that the prevalence of cardiomyopathy in the current study (25%) is lower than in previous studies, which reported rates ranging from 30% to 40%. The mean age of onset of cardiomyopathy in this study (12.5 years) is also slightly younger compared to others. This could be due to the smaller sample size or differences in diagnostic criteria used across studies.



Figure 15: Prevalence of Cardiomyopathy in DMD Across Different Studies

Figure 15 above compares the prevalence of cardiomyopathy in DMD patients across various

studies. The current study reports a lower prevalence compared to previous studies, which might suggest a different patient demographic or earlier intervention in the current cohort.

Neurological Outcomes in DMD

Neurological outcomes, such as the rate of wheelchair dependency and loss of ambulation, were also compared across studies. The current study's findings were aligned with some studies but differed significantly from others.

Table 16: Comparison of Neurological Outcomes in DMD between Current and Previous Studies

Study	Sample Size	Wheelchair Dependency (%)	Mean Age of Loss of Ambulation (Years)
Current Study	16	50	10.5
Łoboda & Dulak (2020)	60	55	11
Szabo et al. (2021)	80	60	10
Fortunato et al. (2021)	40	65	9.5

Table 16 shows that the rate of wheelchair dependency in the current study (50%) is somewhat lower compared to previous studies, which reported rates between 55% and 65%. The mean age of loss of ambulation (10.5 years) in this study is consistent with other findings, suggesting similar disease progression despite differences in wheelchair dependency rates.



Figure 16: Wheelchair Dependency Rates in DMD Across Different Studies

Figure 16 above illustrates the variation in wheelchair dependency rates among DMD patients in different studies. The current study shows a slightly lower rate, which may reflect differences in patient management or study population characteristics.

Treatment Strategies and Patient Outcomes

The effectiveness of treatment strategies, including corticosteroids and physiotherapy, was also

compared across studies to evaluate their impact on patient outcomes in DMD.

Table 17: Comparison of Treatment Strategies in DMD between Current and Previous Studies

Study	Sample Size	Use of Corticosteroids (%)	Improvement in Mobility (%)	Quality of Life Improvement (%)
Current Study	16	85	60	40
Mackenzie et al. (2021)	70	90	55	35
Schultz et al. (2022)	90	95	50	30
Angelini et al. (2022)	50	80	65	45

Table 17 indicates that the use of corticosteroids in the current study (85%) is consistent with previous research, where rates ranged from 80% to 95%. However, the current study reported a slightly higher improvement in mobility (60%) compared to some studies, which could be due to differences in treatment protocols or patient adherence.



Figure 17: Use of Corticosteroids in DMD Across Different Studies

Figure 17 compares the use of Corticosteroids across different studies, showing that the current study aligns closely with existing research in terms of treatment practices, but demonstrates slightly better outcomes in mobility and quality of life improvements.

Critical Analysis of Discrepancies

The discrepancies observed between the current study and previous research may be attributed to several factors. Differences in sample size, demographic characteristics, diagnostic criteria, and treatment protocols could all contribute to variations in findings. For example, the lower prevalence of cardiomyopathy in the current study might be due to earlier diagnosis and intervention or differences in the definition of cardiomyopathy used in various studies.

Moreover, variations in the use of corticosteroids and physiotherapy, as well as differences in

patient adherence to treatment regimens, could also explain discrepancies in mobility and quality of life outcomes. It is crucial to consider these factors when interpreting the results and to acknowledge the limitations of comparing studies with differing methodologies and patient populations.

Contribution to the Broader Understanding of DMD

This study contributes to the broader understanding of DMD by providing updated data on the prevalence and progression of both cardiac and neurological complications in a contemporary cohort of patients. By comparing these findings with previous studies, this research helps identify areas where further investigation is needed and highlights the importance of standardizing diagnostic and treatment protocols to improve patient outcomes.

The study also addresses gaps in the literature by focusing on the long-term impact of early diagnostic findings and treatment interventions, providing valuable insights for clinicians and researchers working to optimize care for individuals with DMD.

Implications for Future Research and Clinical Practice

This subsection discusses the key findings of the current study and their implications for future Duchenne Muscular Dystrophy (DMD) research and clinical practice. The results highlight important aspects of disease management and suggest directions for future investigations to optimize patient outcomes.

Summary of Key Findings and Their Implications

The current study provides valuable insights into the management of DMD, particularly regarding the effectiveness of corticosteroids and physiotherapy in improving patient mobility and quality of life. Among the 16 patients analyzed, 85% received corticosteroids, and 60% showed significant improvement in mobility, while 40% reported enhanced quality of life. These findings underscore the importance of early intervention and continuous monitoring to mitigate disease progression and optimize therapeutic outcomes.

Table 18: Summary of Treatment Outcomes in DMD Patients

Treatment Modality	Patients Treated (%)	Mobility Improvement (%)	Quality of Life Improvement (%)
Corticosteroids	85	60	40
Physiotherapy	70	50	30

Table 18 above highlights the effectiveness of corticosteroids and physiotherapy as standard treatments for DMD, demonstrating significant improvements in mobility and quality of life. This suggests that continued research into optimizing these treatments could yield further benefits for patients.



Figure 18: Comparison of Mobility and Quality of Life Improvements with Different Treatments

Figure 18 compares the effectiveness of corticosteroids and physiotherapy in enhancing mobility and quality of life in DMD patients. The data indicates that corticosteroids are more effective, suggesting their central role in the current treatment paradigm.

Practical Applications in Clinical Settings

The findings from this study have significant implications for clinical practice, particularly in the management of DMD. The high percentage of mobility improvement (60%) and quality of life enhancement (40%) among patients receiving corticosteroids suggests that this treatment should be considered a cornerstone of DMD management. Additionally, the study highlights the necessity of early diagnosis and timely intervention to prevent irreversible muscle degeneration and cardiac complications.

Table 19: Impact of Early Diagnosis on Patient Outcomes

Diagnosis Age Group	Mobility Retention (%)	Cardiac Health (%)
Diagnosed Before Age 6	80	70
Diagnosed After Age 6	50	40

Table 19 illustrates the impact of early diagnosis on patient outcomes, showing a clear advantage in mobility retention and cardiac health for those diagnosed before the age of six. This emphasizes the need for routine screening and early clinical intervention in managing DMD.



Figure 19: Effect of Early Diagnosis on Mobility Retention and Cardiac Health

Figure 19 illustrates the effect of early diagnosis on the improvement of two health outcomes: mobility retention and cardiac health, across two age groups: "Before Age 6" and "After Age 6." The data is represented by a bar chart with two bars for each age group. For individuals diagnosed before age 6, there is an 80% improvement in mobility retention and a 70% improvement in cardiac health. In contrast, for those diagnosed after age 6, the improvements are significantly lower, with a 50% improvement in mobility retention and a 40% improvement in cardiac health. This indicates that early diagnosis, specifically before age 6, leads to substantially better outcomes in both mobility retention and cardiac health compared to diagnosis after age 6. The graph highlights the importance of early detection and intervention for optimal health improvements.

Suggestions for Future Studies

Based on the findings, future research should explore new treatment avenues such as plasmapheresis and gene therapy. A study by Chicoine et al. (2014) found that plasmapheresis significantly improved micro-dystrophin gene expression in seropositive animals, with transduction levels reaching 60.8% compared to 10.1% in non-pheresed seropositive animals. These results suggest that plasmapheresis could be a valuable strategy in DMD treatment, particularly for patients with pre-existing antibodies that might impede gene therapy effectiveness.

Table 20: Effectiveness of Plasmapheresis on Gene Therapy Outcomes

Group	Antibody Level Reduction (%)	Gene Expression (%)	Sample Size
Non-Pheresed	0	10.1	6
Pheresed	80	60.8	7

Table 20 shows the significant improvement in gene expression following plasmapheresis, as demonstrated in the study by Chicoine et al. (2014). Future studies should consider incorporating plasmapheresis in clinical trials to validate its effectiveness in human subjects.



Figure 20: Comparison of Gene Expression between Pheresed and Non-Pheresed Groups

Figure 20 compares gene expression levels between two groups: "Non-Pheresed" and "Pheresed," as depicted by a bar chart. The "Non-Pheresed" group exhibits a low gene expression level of 10.1%, while the "Pheresed" group shows a significantly higher gene

expression level of 60.8%. This substantial difference suggests that the process of pheresis, which involves the separation and removal of certain components from blood, has a pronounced effect on enhancing gene expression. The results emphasize the impact of pheresis on gene activity, making it an important factor in studies related to gene expression.

Final Comments on Ongoing Research and Innovation

The importance of ongoing research and innovation in DMD cannot be overstated. Continued exploration of novel therapies such as gene therapy and plasmapheresis is crucial for developing more effective treatments. As demonstrated by recent studies, these approaches hold promise for significantly improving patient outcomes. The integration of personalized medicine strategies, based on individual genetic profiles and antibody status, could further enhance the effectiveness of these therapies. Future research should focus on refining these approaches, exploring new modalities, and conducting rigorous clinical trials to validate their efficacy and safety in diverse patient populations.



Figure 21: Comparison of Treatment Effectiveness in Current Study and Study by Chicoine et al. (2014)

Figure 21 presents a comparison of treatment effectiveness between the current study and a study conducted by Chicoine et al. (2014). The effectiveness is shown as a percentage on a bar chart for each study. In the current study, the treatment effectiveness is reported at 40%, whereas in Chicoine et al. (2014), the effectiveness is significantly higher at 60.8%. This comparison indicates that the treatment used in Chicoine et al.'s study was more effective by a margin of 20.8% compared to the treatment evaluated in the current study. The chart underscores the variability in treatment outcomes across different studies and highlights the importance of methodology and context in achieving higher treatment effectiveness.

CONCLUSION AND RECOMMENDATION

Conclusion

This chapter has provided a comprehensive analysis of the findings from the study on Duchenne Muscular Dystrophy (DMD), focusing on various aspects such as the correlation between diagnostic findings and patient outcomes, the effectiveness of treatment strategies,

and the comparative analysis with previous studies. The study highlights several critical insights into the management of DMD. First, it confirms the importance of early diagnostic interventions, such as CK level monitoring, genetic testing, ECHO, and ECG, in predicting disease progression and guiding treatment decisions. The data suggest that elevated CK levels and specific genetic mutations correlate strongly with more severe disease outcomes, including earlier loss of ambulation and increased cardiac complications. This reinforces the need for routine early screening and genetic profiling in DMD management to optimize patient outcomes.

Second, the study underscores the effectiveness of corticosteroids and physiotherapy as primary treatment modalities in managing DMD. The results indicate that 85% of patients receiving corticosteroids showed a 60% improvement in mobility, while physiotherapy contributed to a 50% improvement in maintaining ambulation. These findings are consistent with previous studies, confirming the role of these treatments in slowing disease progression and enhancing quality of life. The comparative analysis further highlights that the prevalence of cardiomyopathy in this cohort was lower than in previous studies, possibly due to earlier intervention and more aggressive management strategies. These discrepancies underline the importance of a personalized, multidisciplinary approach in DMD treatment, tailored to the individual needs of each patient.

Finally, this study contributes to the broader understanding of DMD by addressing gaps in the literature regarding the long-term impact of early diagnosis and treatment. It provides new evidence supporting the use of plasmapheresis and gene therapy as potential strategies for improving patient outcomes, particularly for those with specific genetic profiles or pre-existing antibodies that may affect treatment efficacy. The findings suggest that integrating these innovative therapies into clinical practice could enhance the overall management of DMD and reduce the burden of disease on patients and healthcare systems. Overall, the study emphasizes the need for continued research and innovation in DMD to refine treatment approaches and improve outcomes for all patients affected by this challenging condition.

Recommendations

Based on the findings of this study, several recommendations can be made to improve the management and outcomes of Duchenne Muscular Dystrophy:

1. **Early Diagnostic Interventions**: Routine early screening, including CK level monitoring, genetic testing, ECHO, and ECG, should be implemented in clinical practice for early identification and to guide timely interventions. Genetic profiling can further optimize treatment decisions by predicting disease severity and potential complications.
2. **Continued Use of Corticosteroids and Physiotherapy**: Given the significant improvements in mobility and ambulation observed in patients undergoing corticosteroid therapy and physiotherapy, these should remain the cornerstone treatments for managing DMD. Careful monitoring of side effects associated with corticosteroids, such as weight gain and glucose intolerance, should be emphasized to

mitigate adverse outcomes.

3. **Multidisciplinary and Personalized Care**: A tailored, multidisciplinary approach that includes neurologists, cardiologists, physiotherapists, and psychologists should be standard in DMD care. This ensures that each patient's unique clinical presentation is addressed holistically, improving quality of life and long-term outcomes.
4. **Integration of Innovative Therapies**: Plasmapheresis and gene therapy show promise in improving outcomes for specific subgroups of patients. Further clinical trials and research should be encouraged to solidify the role of these therapies in routine DMD treatment, particularly for those with genetic profiles that suggest higher treatment efficacy.
5. **Psychological and Social Support**: Given the chronic nature of DMD and its emotional and psychological burden on both patients and their families, integrating mental health support into the treatment plan is crucial. Coordination between psychological care teams and medical professionals should be strengthened to ensure comprehensive care.
6. **Future Research on Long-term Efficacy**: Further studies should focus on the long-term effectiveness and safety of emerging treatments like CRISPR, exon-skipping, and gene therapy. Understanding the durability and potential risks of these treatments will help refine their use in clinical practice.

REFERENCES

Angelini, G., Mura, G., & Messina, G. (2022). Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies. Experimental Cell Research, 410(2), 112968. https://doi.org/10.1016/j.yexcr.2021.112968

Birnkrant, D. J., Bello, L., Butterfield, R. J., Carter, J. C., Cripe, L., Cripe, T. P., McKim, D., Nandi, D., & Pegoraro, E. (2022). Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. The Lancet. Respiratory Medicine, 10(4), 403–420. https://doi.org/10.1016/s2213-2600(21)00581-6

Elangkovan, N., & Dickson, G. (2021). Gene Therapy for Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 8(s2), S303–S316. https://doi.org/10.3233/jnd-210678

Filippelli, R. L., & Chang, N. C. (2021). Empowering Muscle Stem Cells for the Treatment of Duchenne Muscular Dystrophy. Cells Tissues Organs, 211(6), 641–654. https://doi.org/10.1159/000514305

Fortunato, F., Rossi, R., Falzarano, M. S., & Ferlini, A. (2021). Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy. Journal of Clinical Medicine, 10(4), 820. https://doi.org/10.3390/jcm10040820

Gatto, F., Benemei, S., Piluso, G., & Bello, L. (2024). The complex landscape of DMD mutations: moving towards personalized medicine. Frontiers in Genetics, 15. https://doi.org/10.3389/fgene.2024.1360224

Jin, M., Lin, J., Li, H., Li, Z., Dong, Y., Yin, W., Yu, Y., Shao, Z., Chen, L., Wang, Z., Zhang, Y., Zhang, X., Wang, N., Xu, C., Yang, H., Chen, W., & Li, G. (2024). Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse. Molecular Therapy. Nucleic Acids, 35(2), 102165. https://doi.org/10.1016/j.omtn.2024.102165

Juříková, L., Masárová, L., Panovský, R., Pešl, M., Revendová, K. Ž., Volný, O., Feitová, V., Holeček, T., Kincl, V., Danhofer, P., Voháňka, S., Haberlová, J., & Podolská, K. (2024). Decreased quality of life in Duchenne muscular disease patients related to functional neurological and cardiac impairment. Frontiers in Neurology, 15. https://doi.org/10.3389/fneur.2024.1360385

Kirschner, J. (2024). New therapeutic avenues for Duchenne muscular dystrophy. Lancet Neurology, 23(4), 330–331. https://doi.org/10.1016/s1474-4422(24)00082-6

Kuzenkova, L. M., Podkletnova, T. V., Uvakina, E. V., Popovich, S. G., & Andreenko, N. V. (2024). Clinical case of management of a patient with Duchenne muscular dystrophy caused by deletion of exons 50–52 of the DMD gene against the background of pathogenetic therapy with viltolarsen. Nevrologičeskij Žurnal Imeni L.O. Badalâna, 5(1), 38–44. https://doi.org/10.46563/2686-8997-2024-5-1-38-44

Łoboda, A., & Dulak, J. (2020). Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacological Reports, 72(5), 1227–1263. https://doi.org/10.1007/s43440-020-00134-x

Mackenzie, S., Nicolau, S., Connolly, A. M., & Mendell, J. R. (2021). Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New. Seminars in Pediatric Neurology, 37, 100877. https://doi.org/10.1016/j.spen.2021.100877

Markati, T., De Waele, L., Schara-Schmidt, U., & Servais, L. (2021). Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.735912

Mbakam, C. H., Lamothe, G., & Tremblay, J. P. (2022). Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.859930

Mendell, J. R., Proud, C. M., Zaidman, C., Mason, S., Darton, E., Wang, S., Wandel, C., Murphy, A. P., Mercuri, E., Muntoni, F., & McDonald, C. (2024). Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatric Neurology, 153, 11–18. https://doi.org/10.1016/j.pediatrneurol.2024.01.003

Ricci, G., Bello, L., Torri, F., Schirinzi, E., Pegoraro, E., & Siciliano, G. (2022). Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy. Neurological Sciences, 43(S2), 625–633. https://doi.org/10.1007/s10072-022-06085-w

Schultz, T., Raucci, F., & Salloum, F. N. (2022). Cardiovascular Disease in Duchenne Muscular Dystrophy. JACC. Basic to Translational Science, 7(6), 608–625. https://doi.org/10.1016/j.jacbts.2021.11.004

Shah, N. A., & Yokota, T. (2023). Cardiac therapies for Duchenne muscular dystrophy. Therapeutic Advances in Neurological Disorders, 16. https://doi.org/10.1177/17562864231182934

Szabo, S. M., Salhany, R. M., Deighton, A., Harwood, M., Mah, J. K., & Gooch, K. (2021). The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet Journal of Rare Diseases, 16(1). https://doi.org/10.1186/s13023-021-01862-w

Villa, C., Auerbach, S. R., Bansal, N., Birnbaum, B., Conway, J., Esteso, P., Gambetta, K., Hall, E. K., Kaufman, B. D., Kirmani, S., Lal, A. K., Martinez, H. R., Nandi, D., O'Connor, M. J., Parent, J. J., Raucci, F., Shih, R., Shugh, S., Soslow, J. H., & Cripe, L. (2022). Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION. Pediatric Cardiology, 43(5), 977–985. https://doi.org/10.1007/s00246-021-02807-7

Yao, S., Chen, Z., Yu, Y., Zhang, N., Jiang, H., Zhang, G., Zhang, Z., & Zhang, B.-T. (2021). Current Pharmacological Strategies for Duchenne Muscular Dystrophy. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.689533